OK2

OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research[1].

Product Specifications

UNSPSC

12352209

Target

EGFR; STAT

Type

Peptides

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/ok2.html

Purity

99.13

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@H](C)[C@@H](C(N1)=O)NC([C@H](CC2=CNC3=CC=CC=C32)NC([C@@H]4CCCN4C([C@H](CCCNC(N)=N)NC([C@H](CC5=CNC=N5)NC([C@H](CCCCN)NC([C@@H]1[C@H](O)C)=O)=O)=O)=O)=O)=O

Molecular Formula

C42H62N14O9

Molecular Weight

907.03

References & Citations

[1]Dong J, et.al. Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment. J Med Chem. 2023 Jun 22;66 (12) :8251-8266.